Display options
Cite
Na YS, Jang S, Hong S, et al. Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome. Tuberc Respir Dis (Seoul). 2019;82(1):53-61doi: 10.4046/trd.2018.0045.
Na, Y. S., Jang, S., Hong, S., Oh, Y. M., Lee, S. D., & Lee, J. S. (2019). Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome. Tuberculosis and respiratory diseases, 82(1), 53-61. https://doi.org/10.4046/trd.2018.0045
Na, Yong Sub, et al. "Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome." Tuberculosis and respiratory diseases vol. 82,1 (2019): 53-61. doi: https://doi.org/10.4046/trd.2018.0045
Na YS, Jang S, Hong S, Oh YM, Lee SD, Lee JS. Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome. Tuberc Respir Dis (Seoul). 2019 Jan;82(1):53-61. doi: 10.4046/trd.2018.0045. PMID: 30574689; PMCID: PMC6304333.
Copy Download .nbib Format: NLM
Share it on

Tuberc Respir Dis (Seoul). 2019 Jan;82(1):53-61. doi: 10.4046/trd.2018.0045.

Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome.

Tuberculosis and respiratory diseases

Yong Sub Na, Seongsoo Jang, Seokchan Hong, Yeon Mok Oh, Sang Do Lee, Jae Seung Lee

Affiliations

  1. Department of Pulmonary and Critical Care Medicine, Chosun University Hospital, Gwangju, Korea.
  2. Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  3. Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  4. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  5. Department of Pulmonary and Critical Care Medicine, Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. [email protected].

PMID: 30574689 PMCID: PMC6304333 DOI: 10.4046/trd.2018.0045

Abstract

BACKGROUND: Antiphospholipid antibody syndrome (APS), an important cause of acquired thrombophilia, is diagnosed when vascular thrombosis or pregnancy morbidity occurs with persistently positive antiphospholipid antibodies (aPL). APS is a risk factor for unprovoked recurrence of pulmonary embolism (PE). Performing laboratory testing for aPL after a first unprovoked acute PE is controversial. We investigated if a specific phenotype existed in patients with unprovoked with acute PE, suggesting the need to evaluate them for APS.

METHODS: We retrospectively reviewed patients with PE and APS (n=24) and those with unprovoked PE with aPL negative (n=44), evaluated 2006-2016 at the Asan Medical Center. We compared patient demographics, clinical manifestations, laboratory findings, and radiological findings between the groups.

RESULTS: On multivariate logistic regression analysis, two models of independent risk factors for APS-PE were suggested. Model I included hemoptysis (odds ratio [OR], 12.897; 95% confidence interval [CI], 1.025-162.343), low PE severity index (OR, 0.948; 95% CI, 0.917-0.979), and activated partial thromboplastin time (aPTT; OR, 1.166; 95% CI, 1.040-1.307). Model II included age (OR, 0.930; 95% CI, 0.893-0.969) and aPTT (OR, 1.104; 95% CI, 1.000-1.217).

CONCLUSION: We conclude that patients with first unprovoked PE with hemoptysis and are age <40; have a low pulmonary embolism severity index, especially in risk class I-II; and/or prolonged aPTT (above 75th percentile of the reference interval), should be suspected of having APS, and undergo laboratory testing for aPL.

Copyright©2019. The Korean Academy of Tuberculosis and Respiratory Diseases.

Keywords: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Phenotype; Pulmonary Embolism; Risk Factors

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

  1. J Autoimmun. 2000 Sep;15(2):145-51 - PubMed
  2. Ann Rheum Dis. 2002 Mar;61(3):195-8 - PubMed
  3. Arthritis Rheum. 2002 Apr;46(4):1019-27 - PubMed
  4. Blood. 2003 Mar 1;101(5):1827-32 - PubMed
  5. Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16 - PubMed
  6. Am J Med. 2004 Jun 15;116(12):816-28 - PubMed
  7. Am J Respir Crit Care Med. 2005 Oct 15;172(8):1041-6 - PubMed
  8. J Thromb Haemost. 2006 Feb;4(2):295-306 - PubMed
  9. J Thorac Imaging. 2006 Mar;21(1):1-7 - PubMed
  10. Ann Clin Lab Sci. 2007 Winter;37(1):3-14 - PubMed
  11. Blood Rev. 2008 Jul;22(4):187-94 - PubMed
  12. Thromb Haemost. 2008 Nov;100(5):943-8 - PubMed
  13. Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):298-310 - PubMed
  14. J Thromb Haemost. 2009 Oct;7(10):1737-40 - PubMed
  15. J Thromb Haemost. 2010 Jul;8(7):1509-14 - PubMed
  16. Arch Intern Med. 2010 Oct 25;170(19):1710-6 - PubMed
  17. Lancet. 2010 Dec 11;376(9757):2032-9 - PubMed
  18. J Am Coll Cardiol. 2011 Feb 8;57(6):700-6 - PubMed
  19. Lupus. 2011 Feb;20(2):206-18 - PubMed
  20. Lupus. 2011 Jul;20(8):876-85 - PubMed
  21. Br J Haematol. 2012 Apr;157(1):47-58 - PubMed
  22. Am J Hematol. 2012 May;87 Suppl 1:S63-7 - PubMed
  23. Curr Pharm Des. 2014;20(4):545-51 - PubMed
  24. J Autoimmun. 2014 Feb-Mar;48-49:20-5 - PubMed
  25. Blood. 2014 Mar 20;123(12):1794-801 - PubMed
  26. Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k - PubMed
  27. Medicine (Baltimore). 2015 Oct;94(41):e1488 - PubMed
  28. J Thromb Thrombolysis. 2016 Jan;41(1):32-67 - PubMed
  29. Chest. 2016 Feb;149(2):315-352 - PubMed
  30. Blood. 2018 May 10;131(19):2151-2160 - PubMed
  31. Am J Med. 1982 Apr;72(4):599-606 - PubMed
  32. J Rheumatol. 1995 Jan;22(1):62-6 - PubMed
  33. Haematologica. 1993 Sep-Oct;78(5):313-8 - PubMed
  34. Ann Rheum Dis. 1997 Mar;56(3):194-6 - PubMed
  35. Circulation. 1998 Jun 9;97(22):2195-6 - PubMed

Publication Types